Vasculitis: Clinical Trials

828 trials for Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

344 completed, 175 recruiting, 142 unknown, 52 not yet recruiting. 161 Phase 2, 125 Not applicable, 112 Phase 3, 82 Phase 1, 57 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2161Completed 70, Recruiting 25, Unknown 22, Terminated 15, Active not recruiting 11, Not yet recruiting 9, Withdrawn 9
Not applicable125Completed 57, Unknown 29, Recruiting 21, Terminated 9, Not yet recruiting 6, Withdrawn 2, Enrolling by invitation 1
Phase 3112Completed 56, Recruiting 17, Unknown 12, Terminated 10, Active not recruiting 8, Not yet recruiting 6, Withdrawn 3
Phase 182Completed 35, Recruiting 21, Active not recruiting 6, Not yet recruiting 6, Unknown 6, Terminated 4, Enrolling by invitation 2, Withdrawn 2
Phase 457Unknown 15, Recruiting 14, Completed 12, Terminated 6, Not yet recruiting 5, Enrolling by invitation 2, Active not recruiting 1, Suspended 1, Withdrawn 1
Early Phase 123Recruiting 7, Not yet recruiting 4, Completed 3, Unknown 3, Terminated 2, Withdrawn 2, Active not recruiting 1, Suspended 1

Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy
Early Phase 1Not yet recruitingGrit Biotechnology302027-08-012026-09-11
Reducing Arterial Inflammation Using Eplerenone and Statins in HIV
Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD)
Phase 2 / Phase 3Not yet recruitingMassachusetts General Hospital1242027-03-012026-10-23
Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease
BOTOX INJECTION - Buerger Disease, Raynaud Syndrome
Phase 3Not yet recruitingUniversity Hospital, Toulouse82027-01-012026-07-23
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
[18F]FDG Long-Axial Field of View (LAFOV)-PET/CT, CT Angiogram, MR Angiogram - Large Vessel Vasculitis, Takayasu Arteritis
Not applicableNot yet recruitingImperial College London182026-12-012026-10-16
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2Not yet recruitingPeking University Third Hospital92026-11-012026-09-23
Cardiac Imaging in Systemic Disorders: the ORACLES Registry
data collection - Lupus
Not yet recruitingAssistance Publique - Hôpitaux de Paris15002026-11-012026-02-13
Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
IVIG, Aspirin, Firsekibart - Kawasaki Disease
Phase 2 / Phase 3Not yet recruitingChildren's Hospital of Fudan University902026-11-012026-10-22
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Bedside quantitative sensory testing - Rheumatic Diseases, Lupus Erythematosus, Systemic
Not yet recruitingNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2252026-11-012026-10-27
Qualitative Study With Focus Groups of People Living With ANCA-associated Vasculitis (AAV) and Clinicians, to Explore Different Perspectives on Shared Decision-making in AAV.
ANCA Associated Vasculitis (AAV)
Not yet recruitingUniversity of the West of England802026-10-012026-10-06
Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)
Zirconium Zr 89 labelled rituximab - Giant Cell Arteritis (GCA)
Not yet recruitingUniversity of Edinburgh302026-10-012026-06-16
FT839 in Autoimmune Diseases
FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM)
Phase 1 / Phase 2RecruitingFate Therapeutics4462026-10-012026-09-02
Clinical, Laboratory, and Therapeutic Analysis of Behçet's Disease in Assiut
Behçet's Disease
Not yet recruitingAssiut University302026-09-302025-09-05
Serum EBI-3 Protein Levels in Behçet's Disease
Behçet Disease
Not yet recruitingAssiut University902026-09-262026-09-28
Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.
Repository Corticotropin Injection (ACTH), Study-matched inactive placebo injection, also called control injection - Behçet's Syndrome, Behçet's Syndrome (BS)
Phase 2Not yet recruitingPeking University People's Hospital602026-09-012026-09-22
Asprosin in Behect Patients
Behcet Disease
Not yet recruitingAssiut University442026-09-012026-09-03
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
RD06-05 CAR-T Cell Injection - SLE - Systemic Lupus Erythematosus, Systemic Sclerosis
Early Phase 1Not yet recruitingNanjing Bioheng Biotech Co., Ltd.302026-09-012026-07-16
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Pericarditis, Tako-TSUBO Cardiomyopathy
Not yet recruitingAssistance Publique - Hôpitaux de Paris3002026-09-012026-08-10
Pain-Sleep in Rheumatic Disease
Better Nights, Better Days for Youth - Rheumatic Diseases, Arthritis
Not applicableNot yet recruitingThe Hospital for Sick Children432026-09-012026-08-20
Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis
Obinutuzumab beta, Glucocorticoids - ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV)
Phase 2RecruitingChinese PLA General Hospital202026-08-212026-09-15
Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis
BBD-1 Multi target Immune Enhancement Targeting Agent - Allergic Reaction (IgA) Vasculitis
Phase 2RecruitingQifeng Zhang302026-08-102026-08-11

Showing 20 of 828. Sign in to see all of them.

Narrower conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (153)  ·  Giant Cell Arteritis (145)  ·  Behcet Syndrome (131)  ·  Granulomatosis with Polyangiitis (104)  ·  Lupus Erythematosus, Systemic (76)  ·  Takayasu Arteritis (76)  ·  Microscopic Polyangiitis (69)  ·  Mucocutaneous Lymph Node Syndrome (62)  ·  Churg-Strauss Syndrome (61)  ·  Scleroderma, Systemic (51)  ·  Myositis (48)  ·  Phlebitis (44)  ·  Arthritis, Rheumatoid (43)  ·  IgA Vasculitis (33)

Broader conditions

Vascular Diseases (815)  ·  Cardiovascular Diseases (808)  ·  Skin and Connective Tissue Diseases (696)  ·  Skin Diseases (670)  ·  Skin Diseases, Vascular (647)  ·  Immune System Diseases (487)  ·  Autoimmune Diseases (427)  ·  Nervous System Diseases (302)  ·  Systemic Vasculitis (247)  ·  Central Nervous System Diseases (226)  ·  Brain Diseases (224)  ·  Cerebrovascular Disorders (221)  ·  Arteritis (200)  ·  Hemic and Lymphatic Diseases (190)

Interventions

Rituximab (39)  ·  Cyclophosphamide (38)  ·  Prednisone (34)  ·  tocilizumab (25)  ·  Azathioprine (23)  ·  Infliximab (20)  ·  Blood Specimen Collection (18)  ·  Glucocorticoids (18)  ·  Methotrexate (16)  ·  avacopan (15)  ·  Immunoglobulins, Intravenous (14)  ·  Prednisolone (14)  ·  mepolizumab (14)  ·  Mycophenolic Acid (13)  ·  Methylprednisolone (11)

Sponsors

Assistance Publique - Hôpitaux de Paris (51)  ·  University of Pennsylvania (22)  ·  Assiut University (19)  ·  Amgen (17)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (15)  ·  Children's Hospital of Fudan University (13)  ·  Cambridge University Hospitals NHS Foundation Trust (11)  ·  Novartis Pharmaceuticals (11)  ·  Centre Hospitalier Universitaire Dijon (10)  ·  Massachusetts General Hospital (10)  ·  Peking Union Medical College Hospital (10)  ·  Shanghai Zhongshan Hospital (10)  ·  Chinese SLE Treatment And Research Group (8)  ·  University of California, San Diego (8)  ·  GlaxoSmithKline (7)

Countries

United States (206)  ·  France (170)  ·  China (133)  ·  United Kingdom (74)  ·  Canada (62)  ·  Italy (60)  ·  Germany (57)  ·  Turkey (Türkiye) (57)  ·  Spain (34)  ·  Japan (29)  ·  Netherlands (29)  ·  Switzerland (26)  ·  Denmark (24)  ·  Australia (23)  ·  Belgium (23)

Top investigators

Peter A. Merkel, MD, MPH (13)  ·  Peter A Merkel, MD, MPH (10)  ·  Lindi Jiang, PhD (6)  ·  David Jayne (5)  ·  Fang Liu, MD (5)  ·  Fereydoun Davatchi, MD (4)  ·  Peter Merkel, MD, MPH (4)  ·  Raashid A Luqmani, DM FRCP (4)  ·  Ali MA Ismail, lecturer (3)  ·  Amanda M. Terry, MA (3)

Results publications

PMID 36853224, PMID 33164993, PMID 28514601, PMID 36927642, PMID 22429908, PMID 25153486, PMID 25372085, PMID 26952547, PMID 28592297, PMID 28745999, PMID 31719529, PMID 32866179, PMID 33001543, PMID 33596356, PMID 34061144, PMID 34347947, PMID 35612893, PMID 35850947, PMID 37161084, PMID 37316690, PMID 38251561, PMID 38393328, PMID 39425055, PMID 42384439, PMID 10068416, PMID 10761562, PMID 10921388, PMID 10965678, PMID 11059069, PMID 11059125, PMID 11459787, PMID 11786196, PMID 11961015, PMID 12241872, PMID 12401245, PMID 12631091, PMID 12905485, PMID 14558057, PMID 15161982, PMID 15751091, PMID 15838068, PMID 15947991, PMID 15986348, PMID 16122679, PMID 16142864, PMID 16221103, PMID 16362893, PMID 16378799, PMID 16646004, PMID 16914703

NIH funding

U54AR057319 (13), 2023 (9), 2018 (7), 2016 (5), 2019 (4), 2009 (3), 2014 (3), 2017 (3), 2025 (3), P01DK058335 (3), 2015 (2), R01HL115041 (2), 2008 (1), 268200700036C-5-0-1 (1), P30CA043703 (1)